Tadros Mariam, Rente Lavastida Dianella, Hanna Ashraf
College of Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, USA.
Infectious Diseases, St. George's University School of Medicine, True Blue, GRD.
Cureus. 2024 Jul 24;16(7):e65261. doi: 10.7759/cureus.65261. eCollection 2024 Jul.
This case report discusses the use of intravenous (IV) ketamine as a potential therapeutic agent for early-onset dementia. A 56-year-old female with a diagnosis of early-onset dementia showed significant cognitive decline despite trying and failing several standard treatments such as memantine, donepezil, and rivastigmine. Given the promising results of ketamine in other neurological and psychiatric disorders, the patient underwent a series of IV ketamine infusions over a period of two months. Following treatment, there was a notable improvement in cognitive function, mood, and daily living activities. By the end of her treatments, the patient stated she had more mental clarity, increased focus, improved memory, and increased energy. This case highlights the potential use of ketamine as a novel treatment approach for early-onset dementia and warrants further investigation in larger clinical trials.
本病例报告讨论了静脉注射氯胺酮作为早发性痴呆潜在治疗药物的应用。一名56岁被诊断为早发性痴呆的女性，尽管尝试了几种标准治疗方法，如美金刚、多奈哌齐和卡巴拉汀，但均未成功，仍出现了显著的认知衰退。鉴于氯胺酮在其他神经和精神疾病中取得的有前景的结果，该患者在两个月的时间里接受了一系列静脉注射氯胺酮治疗。治疗后，认知功能、情绪和日常生活活动有了显著改善。在治疗结束时，患者表示她的思维更清晰、注意力增强、记忆力改善且精力更充沛。本病例突出了氯胺酮作为早发性痴呆一种新治疗方法的潜在用途，值得在更大规模的临床试验中进一步研究。
